Study Details

Back to Search Results

A Study of ASP2215 versus Salvage Chemotherapy In Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03182244

Astellas Study ID

The unique identification code given by the study sponsor.

2215-CL-0303

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Leukemia - AML

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 Years - N/A

Sex

Female & Male

Product

gilteritinib

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 2018 - Mar 2026

Masking

None (Open Label)

Enrollment number

276

Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP2215 versus Salvage Chemotherapy In Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site RU501

Saint Petersburg, Russian Federation

Site SG403

Singapore, Singapore

Site CN113

Zhengzhou, China

Site CN126

Shanghai, China

Site CN133

Lanzhou, China

Site MY301

Johor Bahru, Malaysia

Site CN108

Beijing, China

Site CN122

Xi'an, China

Site CN117

Jinan, China

Site CN119

Fuzhou, China

Site MY305

George Town, Malaysia

Site TH202

Khon Kaen, Thailand

Site CN128

Nanjing, China

Site MY304

Kota Kinabalu, Malaysia

Site CN105

Wuhan, China

Site TH204

Chiang Mai, Thailand

Site CN120

Changsha, China

Site RU503

Tula, Russian Federation

Site CN102

Guangzhou, China

Site CN112

Beijing, China

Site RU506

Kemerovo, Russian Federation

Site CN110

Beijing, China

Site CN101

Tianjin, China

Site MY306

Ampang, Malaysia

Site SG401

Singapore, Singapore

Site RU507

Saint Petersburg, Russian Federation

Site CN109

Beijing, China

Site RU502

Saint-Petersburg, Russian Federation

Site TH205

Bangkok, Thailand

Site RU508

Moscow, Russian Federation

Site MY302

Kuala Lumpur, Malaysia

Site TH201

Khon Kaen, Thailand

Site SG402

Singapore, Singapore

Site TH203

Bangkok, Thailand

Site CN129

Shanghai, China

Site CN136

Zhengzhou, China

Site CN121

Guangzhou, China

Site MY303

Pulau Pinang, Malaysia

Site RU504

Krasnoyarsk, Russian Federation

Site CN125

Shenyang, China

Site RU509

Moscow, Russian Federation

Site CN131

Beijing, China

Site CN132

Zhangzhou, China

Site CN106

Qingdao, China

Site CN130

Guiyang City, China

Site CN116

Changchun, China

Site CN114

Guangzhou, China

Site CN118

Hefei, China

Site CN123

Huangpu Qu, China

Site CN107

Hangzhou, China

Site CN103

Beijing, China

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo